// App-Quantinova.ai

: Obinutuzumab-Based Immunochemotherapy Prolongs Progression-Free Survival and Time to Next Anti-Lymphoma Treatment in Patients with Previously Untreated Follicular Lymphoma: Four-Year Results from the Phase III GALLIUM Study

Researchers

Presenter

  • William Townsend

Principal Investigators

  • Guillaume Cartron

  • David Cunningham

  • Martin JS Dyer

  • John G. Gribben

  • Georg Hess

  • Takayuki Ishikawa

  • Ulrich Keller

  • Michael Kneba

  • Ram Malladi

  • Jeffrey D Neidhart

  • Chiara Rusconi

  • Jun Zhu

  • Olivier Catalani

  • Andrea Knapp

  • Harald Zeuner

  • Michael Herold

  • Wolfgang Hiddemann

  • Robert Marcus

Medical Centers

  • Cancer Research UK & UCL Cancer Trials Centre, London, United Kingdom

  • Universitatsklinikum Ulm, Ulm, Germany

  • CHU de Montpellier, Montpellier, France

  • Royal Marsden Hospital, Surrey, United Kingdom

  • The Ernest and Helen Scott Haematological Research Institute, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom

  • Guy's Hospital, London, United Kingdom

  • Universitatsmedizin der Johannes Gutenberg-Universitat Mainz, Mainz, Germany

  • Kobe City Medical Center General Hospital, Kobe, Japan

  • Klinikum rechts der Isar der TU Muenchen, Munich, Germany

  • Universitatsklinikum Schleswig-Holstein, Kiel, Germany

  • Queen Elizabeth Hospital, Birmingham, United Kingdom

  • San Juan Onc Assoc, Farmington, NM

  • Grande Ospedale Metropolitano Niguarda, Milan, Italy

  • Beijing Sanhuan Cancer Hospital, Beijing, China

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • HELIOS Klinikum Erfurt GmbH, Erfurt, Germany

  • Department of Neurosurgery, Ludwig-Maximilians University Munich, Munich, Germany

  • Kings College London, London, United Kingdom

Locations

  • United Kingdom

  • Germany

  • France

  • Japan

  • United States

  • Italy

  • China

  • Switzerland

Companies

  • F. Hoffmann-La Roche

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Follicular lymphoma

Biomarkers

  • DNA Damage Inducible Transcript 3

Drug/Treatment

  • Obinutuzumab

  • Obinutuzumab Intravenous

  • Bendamustine

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT01332968

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved